Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 3
2(50.0%)
4Total
N/A(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03010202Phase 3Unknown

The PROLONG Trial - Rituximab Maintenance Therapy in ITP

Role: collaborator

NCT05824039Not ApplicableCompleted

Safety and Efficacy of Medicinal Plant Extract in Overweight and Obese Participants.

Role: collaborator

NCT05406960Not ApplicableCompleted

Therapeutic Effect of Herbal Infusion on Menometrorrhagia

Role: collaborator

NCT04405921Phase 3Unknown

Hydroxychloroquine, Azithromycin in the Treatment of Covid-19

Role: lead

NCT02578004Completed

Risk Factors for Pressure Ulcers

Role: lead

All 5 trials loaded